IMPRiND Project

Nature Communication by partner UBx

Erwan Bezard & colleagues report a nano-scale exploration of extracellular space features relevant for the #Parkinsons-associated α-synuclein propagation hypothesis & they suggest matrix manipulation could be a disease-modifying strategy. Read the communication.

Publication in Nature by IMPRiND partner Michel Goedert.

New insights into the cryo-EM structures of alpha-synuclein filaments isolated from MSA and DLB brain by IMPRiND partner Michel Goedert. Read the article.

Draft future IMI Call topics published online

The draft texts of the topics that are slated for inclusion in IMI’s next Calls for proposals are published:
  • IMI2 – Call 22 is a single-stage Call for proposals designed to support research activities that will build on, and add value to, results from certain ongoing IMI2 projects.
  • IMI2 – Call 23 is a standard, two-stage Call for proposals with the following topics:
    • Returning clinical trial data to study participants within a GDPR compliant and approved framework
    • Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance This topic is part of IMI’s Antimicrobial Resistance (AMR) Accelerator programme.
    • A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
    • Optimal treatment for patients with solid tumours in Europe through artificial intelligence
    • Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
    • Behavioural model of factors affecting patient adherence
The Calls are both scheduled for launch on 23 June 2020.

To learn more.

The socio-economic impact of IMI projects

12 years and 150 projects later, what kind of socio-economic impact has IMI-funded research had? Read more on the imi.europa website.

Article in the journal Neurol. Neurosurg. Psychiatry by the IMPRiND's Coordinator

Publication by G. Tofaris on Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism Read the article.

Show more posts

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.

© 2019 IMPRiND Project – created by SCIPROMPrivacy policy